Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Slides:



Advertisements
Similar presentations
Medical Management for BPH: The Role of Combination Therapy
Advertisements

Pascal Rischmann  European Urology Supplements 
Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Robotic Cystectomy Versus Open Cystectomy: Are We There Yet?
Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer  Marc Colombel, Mark Soloway, Hideyuki Akaza, Andreas Böhle, Joan Palou, Roger.
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Bladder Cancer: Management and Future Directions
Volume 63, Issue 1, Pages (January 2013)
Volume 63, Issue 4, Pages e53-e56 (April 2013)
Martin C. Michel  European Urology Supplements 
Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer  Marc Colombel, Mark Soloway, Hideyuki Akaza, Andreas Böhle, Joan Palou, Roger.
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Bladder Cancer: A Major Public Health Issue
What is New in Bladder Cancer Diagnosis and Management?
Nomograms for Bladder Cancer
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Towards Early and More Specific Diagnosis of Prostate Cancer
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
A Novel Treatment of Premature Ejaculation
Volume 57, Issue 4, Pages e41-e42 (April 2010)
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Luis Martínez-Piñeiro  European Urology Supplements 
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Richard C. Harkaway  European Urology Supplements 
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Volume 55, Issue 3, Pages (March 2009)
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Philip Toozs-Hobson, Pallavi Latthe  European Urology Supplements 
The Importance of Testosterone Control in Prostate Cancer
Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis
Jacques Irani  European Urology Supplements 
Optimal Testosterone Control and Eligard®
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Neal Shore  European Urology Supplements 
Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH
Long-Term Hormonal Therapy: Who Would Benefit?
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
The Hallmarks of BPH Progression and Risk Factors
Sergio Bracarda  European Urology Supplements 
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Christian Stief  European Urology Supplements 
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
Reevaluating the Health-Related Quality of Life Impact and the Economic Burden of Urgency Urinary Incontinence  Anastasios Athanasopoulos, Salvador Arlandis.
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Richard Berges  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Improving Flexibility and Quality of Life for Your Patients: A Must?
Profile of Silodosin European Urology Supplements
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
Testim® Gel: Review of Clinical Data
Beyond Skeletal-Related Events
Treatment Options in Prostate Cancer Once Primary Therapy Fails
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Bertrand Tombal, Richard Berges
Joaquim Bellmunt  European Urology Supplements 
Classification of Mixed Incontinence
Emmanuel Chartier-Kastler, Andrea Tubaro  European Urology Supplements 
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Jan Roigas  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Michael Marberger  European Urology Supplements 
Morgan Rouprêt, Per-Uno Malmstrom, Peter Black 
Presentation transcript:

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors Karl-Heinz Kurth, Richard J. Sylvester  European Urology Supplements  Volume 6, Issue 14, Pages 789-799 (August 2007) DOI: 10.1016/j.eursup.2007.05.003 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 The distribution of time to invasion in each of the three risk groups. Reproduced with permission from Kurth et al. Eur J Cancer 1995;31:1840–6. European Urology Supplements 2007 6, 789-799DOI: (10.1016/j.eursup.2007.05.003) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Time to first recurrence by recurrence score. O=Observed number of recurrences, N=Number of patients. Reproduced with permission from Sylvester et al. Eur Urol 2006;49:466–75. European Urology Supplements 2007 6, 789-799DOI: (10.1016/j.eursup.2007.05.003) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Time to progression by progression score. O=Observed number of progressions, N=Number of patients. Reprinted with permission from Sylvester et al. Eur Urol 2006;49:466–75. European Urology Supplements 2007 6, 789-799DOI: (10.1016/j.eursup.2007.05.003) Copyright © 2007 European Association of Urology Terms and Conditions